STOCK TITAN

Nurix (NRIX) CSO Hansen converts RSUs, sells 3,214 shares to cover taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported compensation-related stock activity involving vested restricted stock units and a small mandated share sale. On April 30, 2026, she exercised RSUs into a total of 8,608 shares of common stock.

On the same date, she sold 3,214 shares of common stock at a weighted average price of $16.6453 per share solely to cover tax withholding obligations under Nurix’s equity incentive plans. These “sell to cover” transactions were not discretionary trades. After these transactions, she held 120,399 common shares directly.

Positive

  • None.

Negative

  • None.
Insider Hansen Gwenn
Role Chief Scientific Officer
Sold 3,214 shs ($53K)
Type Security Shares Price Value
Exercise Restricted Stock Units 2,000 $0.00 --
Exercise Restricted Stock Units 3,750 $0.00 --
Exercise Restricted Stock Units 2,858 $0.00 --
Exercise Common Stock 2,000 $0.00 --
Exercise Common Stock 3,750 $0.00 --
Exercise Common Stock 2,858 $0.00 --
Sale Common Stock 3,214 $16.6453 $53K
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 117,005 shares (Direct, null)
Footnotes (1)
  1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Shares sold for taxes 3,214 shares Common stock sold on April 30, 2026 to cover tax withholding
Weighted average sale price $16.6453 per share Tax-related sale of 3,214 shares; price range $16.51–$16.78
Shares from RSU vesting/conversion 8,608 shares Common stock acquired via RSU exercises on April 30, 2026
Post-transaction holdings 120,399 shares Common stock directly held after April 30, 2026 transactions
RSU tranche 1 vesting pattern 1/12 quarterly over 3 years First quarterly vesting on July 30, 2023, subject to continued service
RSU tranche 2 vesting pattern 1/12 quarterly over 3 years First quarterly vesting on July 30, 2024, subject to continued service
RSU tranche 3 vesting pattern 1/12 quarterly over 3 years First quarterly vesting on July 30, 2025, subject to continued service
restricted stock units ("RSUs") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
equity incentive plans financial
"mandated by the Issuer's election under its equity incentive plans"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
tax withholding obligations financial
"shares required to be sold ... to cover tax withholding obligations in connection with the vesting"
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hansen Gwenn

(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026M2,000A$0117,005D
Common Stock04/30/2026M3,750A$0120,755D
Common Stock04/30/2026M2,858A$0123,613D
Common Stock04/30/2026S(1)3,214D$16.6453(2)120,399D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(3)04/30/2026M2,000 (4) (5)Common Stock2,000$00D
Restricted Stock Units$0(3)04/30/2026M3,750 (6) (5)Common Stock3,750$015,000D
Restricted Stock Units$0(3)04/30/2026M2,858 (7) (5)Common Stock2,858$022,867D
Explanation of Responses:
1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
4. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
5. RSUs do not expire; they either vest or are canceled prior to the vest date.
6. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
7. The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen04/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Nurix (NRIX) CSO Gwenn Hansen report?

Gwenn Hansen reported RSU vesting and a tax-related share sale. She converted restricted stock units into 8,608 common shares and sold 3,214 shares at a weighted average price of $16.6453 per share to satisfy tax withholding obligations mandated under Nurix’s equity incentive plans.

Was the Nurix (NRIX) insider sale by CSO Gwenn Hansen discretionary?

The sale was not a discretionary trade. Footnotes explain the 3,214-share sale on April 30, 2026 was required to cover tax withholding from RSU vesting, under a mandated “sell to cover” mechanism in Nurix’s equity incentive plans, rather than a voluntary market decision.

How many Nurix (NRIX) shares does CSO Gwenn Hansen hold after these transactions?

After the reported transactions, she held 120,399 common shares directly. This balance reflects RSU conversions totaling 8,608 shares and a 3,214-share sale to cover taxes, as shown in the post-transaction ownership figures in the Form 4 data.

How do Nurix (NRIX) restricted stock units (RSUs) vest for CSO Gwenn Hansen?

Her RSUs vest quarterly over three years. Multiple RSU grants vest as to 1/12 of each total award every quarter over three years, with initial vesting dates on July 30 of 2023, 2024, and 2025, contingent on continued service to Nurix at each vesting date.